You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000–10
  1. Tobias Eggert1,2,
  2. Katherine A McGlynn3,
  3. Austin Duffy1,
  4. Michael Peter Manns2,
  5. Tim F Greten1,
  6. Sean F Altekruse4
  1. 1 Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
  2. 2 Department of Gastroenterology, Hepatology and Endocrinology, School of Medicine, Hannover, Germany
  3. 3 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
  4. 4 Division of Cancer Control and Population Sciences, National Cancer Institute Rockville, Rockville, Maryland, USA
  1. Correspondence to Professor Tim F Greten, Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892, USA; tim.greten{at}nih.gov

https://doi.org/10.1136/gutjnl-2013-305164

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article by Tremosini et al 1 in Gut, which prospectively validated the use of a panel of three antibodies (glypican 3, heat shock protein 70 and glutamine synthetase) for the histopathological diagnosis of hepatocellularcarcinoma (HCC). According to the international classification of diseases for oncology,2 HCC are classified into HCC not otherwise specified (HCC-NOS), which accounts for the vast majority of HCC, fibrolamellar HCC (fHCC), scirrhous HCC, spindle cell variant HCC, clear cell HCC and pleomorphic HCC. While many studies including that by Tremosini and colleagues1 restrict their focus to HCC-NOS, we decided to study fHCC in more depth. fHCC is a rare tumour with limited clinical information available. Current data suggest that demographic attributes of fHCC cases are very different …

    View Full Text

    Footnotes

    • Contributors KAM, AD, MPM, TFG and SFA: study concept; TE and SFA primary data screen; TE, SFA and TFG: data analysis; TFG and SFA wrote manuscript: all authors approved final manuscript. TFG and SFA contributed equally.

    • Funding Funding was provided by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, National Cancer Institute contracts with SEER registries.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles